Inovio Pharmaceuticals

Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. Human data to date have shown a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused pre-cancers and cancers, is in phase II. Other phase I and preclinical programs target prostate, breast, and lung cancers as well as HIV, influenza, malaria and hepatitis. Partners and collaborators include Roche, the University of Pennsylvania, Merck, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative

Blue Bell, US
Size (employees)
157 (est)
Inovio Pharmaceuticals is headquartered in Blue Bell, US

Key People at Inovio Pharmaceuticals

J. Joseph Kim

J. Joseph Kim


Inovio Pharmaceuticals Office Locations

Inovio Pharmaceuticals has office in Blue Bell
Blue Bell, US

Inovio Pharmaceuticals Metrics

Inovio Pharmaceuticals Summary

Market capitalization

$448.8 m

Closing share price

Inovio Pharmaceuticals's current market capitalization is $448.8 m.

Inovio Pharmaceuticals Financials

Inovio Pharmaceuticals's revenue is $13.5 m in FY, 2013 which is a 28.8% increase from the previous period.
FY, 2013FY, 2014FY, 2015


$13.5 m$10.5 m$40.6 m

Revenue growth, %


Operating expense total

$33 m$50 m$74.9 m


($19.5 m)($39.5 m)($34.3 m)

Net Income

($66.1 m)($36.1 m)($29.1 m)

Operating cash flow

$28.1 m$6.8 m$17.1 m

Inovio Pharmaceuticals Market Value History

Inovio Pharmaceuticals Online Presence

Inovio Pharmaceuticals News

Inovio Pharmaceuticals Company Life

You may also be interested in